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Real-world heart rate norms in the Health eHeart study
Robert Avram 1, Geoffrey H. Tison 1, Kirstin Aschbacher1, Peter Kuhar 2, Eric Vittinghoff3, Michael Butzner1, Ryan Runge1,
Nancy Wu1, Mark J. Pletcher3, Gregory M. Marcus1 and Jeffrey Olgin1
Emerging technology allows patients to measure and record their heart rate (HR) remotely by photoplethysmography (PPG) using
smart devices like smartphones. However, the validity and expected distribution of such measurements are unclear, making it
difficult for physicians to help patients interpret real-world, remote and on-demand HR measurements. Our goal was to validate HR-
PPG, measured using a smartphone app, against HR-electrocardiogram (ECG) measurements and describe out-of-clinic, real-world,
HR-PPG values according to age, demographics, body mass index, physical activity level, and disease. To validate the
measurements, we obtained simultaneous HR-PPG and HR-ECG in 50 consecutive patients at our cardiology clinic. We then used
data from participants enrolled in the Health eHeart cohort between 1 April 2014 and 30 April 2018 to derive real-world norms of
HR-PPG according to demographics and medical conditions. HR-PPG and HR-ECG were highly correlated (Intraclass correlation=
0.90). A total of 66,788 Health eHeart Study participants contributed 3,144,332 HR-PPG measurements. The mean real-world HR was
79.1 bpm ± 14.5. The 95th percentile of real-world HR was ≤110 in individuals aged 18–45, ≤100 in those aged 45–60 and ≤95 bpm
in individuals older than 60 years old. In multivariable linear regression, the number of medical conditions, female gender,
increasing body mass index, and being Hispanic was associated with an increased HR, whereas increasing age was associated with
a reduced HR. Our study provides the largest real-world norms for remotely obtained, real-world HR according to various strata and
they may help physicians interpret and engage with patients presenting such data.
npj Digital Medicine            (2019) 2:58 ; https://doi.org/10.1038/s41746-019-0134-9
INTRODUCTION
Heart rate (HR) is a readily available vital sign that holds important
prognostic information. Generally, lower HR has been associated
with lower all-cause and cardiovascular mortality.1–5 Several
studies, as well as expert consensus, indicate that the normal
adult resting HR values lie between 60 and 90 beats per minute
(bpm),1–3 and the American Heart Association defines the normal
sinus HR as between 60 and 100 bpm.3 However, these commonly
accepted norms are derived using in-clinic recorded HR which
may not be representative of the real-world, outside of a
healthcare institution, remotely obtained measurements that are
commonly recorded by a growing number of consumer devices.
For example, clinic measured data can be artificially increased in a
similar phenomenon to “white-coat hypertension”4 or by an
increased adrenergic reaction to the clinical settings.5 In addition,
these measurements do not account for health status, cardiovas-
cular fitness, gender, or racial differences. Moreover, ambulatory
heart rate has been found to be a stronger predictor for all-cause
mortality than in-clinic resting heart rate, yet this real-world
measurement is infrequently obtained.6
Recently, photoplethysmography (PPG) technology has become
nearly ubiquitous in smartphones and wearable sensors (such as
activity trackers or smartwatches), providing both an opportunity
to measure real-world HR while increasing the importance to
understand the accuracy and the normal HR values obtained by
these types of ambulatory measurement.7,8 In addition, physicians
are increasingly being asked by patients to interpret HR values
recorded remotely by patient devices.9 However, in this setting it
is unclear whether traditional clinic-derived normal values
adequately represent remotely recorded real-world data.9
The Health eHeart Study, an online Framingham-like cohort, has
collected a large number of HR measurements over time from
study participants using PPG-enabled smartphone technology.
The goals of this study were to (i) validate HR-PPG measurements
against a gold-standard electrocardiographic HR-
electrocardiogram (ECG) measurement, and (ii) provide real-
world HR-PPG ranges according to age, time, demographics,
comorbidities and chronotropic medication usage, and (iii)
identify predictors of real-world HR-PPG and heart rate
variability (HRV).
RESULTS
Smartphone-based PPG validation
We validated the HR-PPG measurement in 50 consecutive
participants seen at the UCSF general cardiology clinic who had
a 12-lead ECG performed (10 s recording) with simultaneous PPG
signals recorded (Supplementary Figs. 1 and 2). These patients
were older 64.0 ± 13.1 (vs 43.4 ± 14.8 in our full HR data set; p <
0.0005), male (66.0% vs 52.3%; p < 0.00005) and they had a higher
prevalence of diabetes, hypercholesterolemia, hypertension, and
arrhythmia than that in our full HR data set. There were 21
abnormal ECGs (five atrial fibrillation, two atrial flutter, three left
bundle branch block, three frequent premature ventricular
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complex, one frequent premature atrial complex, one sinus
tachycardia, six ventricular pacemaker) and 29 normal ECGs with
normal sinus rhythm. The HR-PPG values had very good intraclass
correlation (ICC) with HR-PPG (0.90 overall; 0.88 for irregular
rhythms; and 1.00 for regular rhythms) with a median absolute HR
difference between both recordings of 2.7 bpm (6.9) (Supplemen-
tary Fig. 3A). The median difference between the two signals in
successive R–R interval measurements was 12.5 ms (23.4) and the
ICC between signals was very high (1.00 overall, 0.99 for irregular
rhythms and 1.00 for regular rhythms) (Supplementary Fig. 3B).
The Bland–Altman plots showed no evidence of trends in either
the bias or the dispersion of the differences, at low, normal, or
high HR values.
Health eHeart study sample
A total of 66,788 Health eHeart Study participants contributed
3,144,332 HR-PPG measurements between April 1 2014 and 30
April 2018, forming our “full HR data set”. Of these, 33,344 (1.06%)
measurements were excluded for being outside of biological
ranges (Supplementary Fig. 4). In our full HR data set, mean age
was 43.3 ± 14.8 years and 47.0% of our participants were female
(Table 1). The BMI was 27.5 ± 5.8 kg/m2 and participants walked on
average 3491.1 ± 3345.4 steps per day, as measured by their
smartphone. Slightly less than half of the participants were
healthy, having reported no medical condition (n= 25,408,
48.3%). The most prevalent medical conditions were hypertension,
hypercholesterolemia and presence of arrhythmia (Table 1). In
addition, 2412 (6.9%) users were treated with beta blockers and
435 (1.3%) were on non-dihydropyridine CCBs, amiodarone, or
inhaled beta agonists (Table 1).
Description of our HR data sets
A total of 40,572 measurements from 8046 participants met our
definition for inclusion in the “known resting HR data set”. After
obtaining real-world user-specific HR-PPG, the geometric mean
HR-PPG in our “known resting HR” data set was 2.8 bpm higher
compared with our “full HR data set” and had a higher spread of
values (81.8 ± 19.6 (95% percentile interval: 52.5–132.1) vs 79.0 ±
14.5 (95% percentile interval: 54.5–110.8), respectively; p < 0.0005
(Supplementary Tables 2A–C, 4 and Fig. 5).
In our “full HR data set”, real-world HR varied significantly over
the day with the lowest values observed between midnight and 5
AM (nadir at 5 am; 75.8 ± 22.4) and the highest values observed
between 5 AM and 5 PM (peak at 5 pm; 82.3 ± 23.7; p < 0.0005)
(Supplementary Fig. 6). The HR was higher during weekdays
compared with weekends (79.1 ± 17.6 vs. 78.4 ± 17.1; p < 0.0005).
Similarly, the HRV was highest between 6 am and 12 pm (14.9 ±
10.6) and lowest between 6 pm and 12 am (12.5 ± 9.6; p < 0.0005
compared with 6 am–12 pm). It was also higher during weekdays
than weekends (13.7 ± 10.7 vs. 13.3 ± 10.4; p < 0.0005) (Supple-
mental Table 1). Finally, the highest average HR was observed
during winter (79.1 ± 16.7), whereas the lowest HR was observed
during fall (78.4 ± 16.5; p < 0.0005 compared with winter). HRV was
highest during summer (15.0 ± 10.2) and fell to the lowest levels
during winter (14.1 ± 10.0; p < 0.0005 compared with summer) and
spring (14.1 ± 10.2; p < 0.0005 compared with summer).
Heart rate according to age, demographics, step count,
comorbidities, and medications
We describe variations in HR-PPG according to various factors
within the subgroup who reported no medical conditions (n=
25,408; 48.3% of users and n= 1,103,570 measurements). These
“healthy individuals” were younger (37.7 ± 13.0 vs. 43.4 ± 14.8; p <
0.0005), with a higher proportion of females (50.2% vs 47.0%; p <
0.0005), similar racial/ethnic group composition, similar step
counts and a lower BMI (26.1 ± 5.3 vs. 28.7 ± 6.0) when compared
with our “full HR data set”. In healthy individuals, average resting
HR-PPG decreased from 81.6 ± 14.0 in those aged 18–20 to 74.2 ±
12.7 in those aged 71–80 (p < 0.0005) (Table 2 and Fig. 1a). The
95th percentile of real-world HR was uniformly under 100 bpm
after 45 years of age reaching approximately 95 bpm at 61 years
of age. Females had on average a HR-PPG 4.4 bpm higher than
men (Fig. 1b). As age increased, the 95% CI of HR-PPG values
narrowed in women more than men (18–20 years, women
56.8–113.1 bpm, men 54.4–106.2 bpm; vs age 60–70, women
56.3–103.7 bpm, men 52.4–101.9 bpm, Fig. 1b and Supplementary
Table 2B, C). African Americans and Asians had the highest HR-
PPG (81.4 ± 14.0 bpm and 79.2 ± 14.3 bpm, respectively) and non-
Hispanic White had the lowest HR-PPG (75.9 ± 14.5 bpm) (Table 2).
HR-PPG increased with BMI from 74.9 ± 16.5 bpm in individuals
with a BMI of 18.5–25 kg/m2 to 80.1 ± 13.3 bpm in those with
BMI ≥ 30 kg/m2 (p < 0.0005). A negative relationship between HR-
PPG and daily step counts was observed, with the HR-PPG values
significantly decreasing from 80.0 ± 13.5 bpm in sedentary
participants walking 2001–4000 steps per day to 78.0 ± 13.9
bpm in active participants walking 8001–12,000 steps per day (p <
0.0005) (Table 2, Fig. 1c and Supplementary Table 3). We observed
no significant difference in the real-world HR-PPG between groups
above an average of 8001 steps per day. Height was a predictor of
reduced heart rate where for every 1 centimeter, the HR was
reduced by 0.23 bpm. In univariable analysis, age, height, and
number of steps were negative predictors of heart rate and female
gender, BMI, Asian race and multi-ethnicity were predictors of an
increased heart rate (Supplementary Table 5). Weight was not a
significant predictor of heart rate. In a multivariable analysis, age
was significantly associated with lowered heart rate, whereas
female gender, BMI, Hispanic ethnicity and the number of medical
conditions had a positive relationship with HR-PPG, however step
counts were not a significant independent predictor of HR-PPG
(Table 4; Model 1).
An increase in average daily steps was associated with higher
HRV, whereas an increase in age and BMI were significant
predictors of a lower HRV (Table 5; Model 1). In Model 2, looking at
age, gender, disease state, and medications, we observed a lower
HRV for increasing age, female gender, hypertension, and an
increase in HRV for Hispanic ethnicity, sleep apnea, and users on
CCB (Table 5; Model 2). No other medical conditions or
medications were significant predictors of HRV in our cohort.
Participants who reported having at least one medical condition
(n= 27,958) contributed two thirds (2,007,418) of the HR-PPG
measurements. They had a higher HR-PPG compared with those
who reported no medical conditions (79.6 ± 14.2 bpm vs 77.6 ±
14.6 bpm, p < 0.0005), even after adjusting for age. Those suffering
from any medical condition, except coronary artery disease, prior
myocardial infarction (MI) and hypercholesterolemia had a
significantly higher HR-PPG than those without the condition
(Table 3). Once adjusting for age, HR was higher in those with
hypercholesterolemia and coronary artery disease. The highest
difference was observed in those with diabetes (82.6 ± 14.1 bpm
vs 78.3 ± 14.5 bpm without diabetes), followed by those with
COPD (82.5 ± 13.9 bpm with vs 78.3 ± 14.5 bpm without COPD). In
multivariable analysis (Table 4, Model 2), female gender, all races/
ethnicities other than non-Hispanic White and participants
suffering from hypertension, hypercholesterolemia, diabetes,
arrhythmia, sleep apnea, COPD, and asthma were independent
predictors of a higher HR-PPG, whereas increasing age was a
predictor of a lower HR-PPG. All medical conditions were
associated with a higher HR-PPG, when adjusting for age, gender,
and beta-blocker use (Supplementary Table 6). Similarly, asthma
and COPD were associated with a higher HR-PPG after adjustment
for beta-agonist use.
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DISCUSSION
As the use of smartphone sensors and wearable devices provides
data on cardiovascular parameters such as HR, physicians are
increasingly expected to help patients interpret the results of
these readings; however, existing norms derived from controlled,
clinical settings may not reflect the range of HR values occurring in
real-world conditions. Our validation demonstrated that
smartphone-based HR-PPG strongly correlates with HR from the
gold-standard ECG. This study provides the first and largest-scale
description of real-world HR values derived from smartphone
Table 1. Baseline characteristics
Baseline characteristics No reported medical
conditions N, (%)
N= 25,408a
Individuals with at least one
medical condition N, (%)
N= 27,958a
Full HR data seta n, (%)
n= 66,788
Validation cohort
n, (%) n= 50
Age, mean ± SD, yrs 37.7 ± 13.0 47.7+ 14.5 43.4 ± 14.8 64.0 ± 13.1
Number of HR-PPG values recorded 1,101,550 1,506,946 3,110,988 –
Number of HR-PPG measurements per
user, per year, median (IQR)
59.7 (143.4) 65.2 (154.4) 60.1 (145.4) 1 (0)
Geometric HR-PPG, mean ± SD, bpm 77.6 ± 14.6 79.6 ± 14.2 79.1 ± 14.5 –
Demographics N= 18,858 N= 18,402 N= 37,240 N= 50
Females 9476 (50.2) 8063 (43.8) 17,519 (47.0) 17 (34.0)
Males 9382 (49.8) 10,339 (56.2) 19,721 (52.3) 33 (66.0)
Race or ethnic group N= 18,727 N= 18,168 N= 37,258 –
Non-Hispanic White 14,280 (76.3) 13,790 (75.9) 28,351 (76.1) –
Black or African 314 (1.7) 486 (2.7) 813 (2.2) –
American Hispanic, Latino, or Spanish
origin or ancestry
2001 (10.7) 1992 (11.0) 4023 (10.7) –
Asian 1160 (6.2) 1028 (5.7) 2212 (5.9) –
Multi-ethnic 526 (2.8) 489 (2.7) 1022 (2.7) –
Other 446 (2.4) 383 (2.1) 837 (2.2) –
Anthropometric data N= 2175 N= 2586 N= 6025 N= 50
Height, mean ± SD, m 1.73 ± 0.10 1.73 ± 0.10 1.73 ± 0.10 1.74 ± 0.11
Weight, mean ± SD, kg 77.9 ± 17.8 86.1 ± 20.8 82.5 ± 19.9 85.8 ± 22.2
BMI, mean ± SD, kg/m2 26.1 ± 5.3 28.7 ± 6.0 27.5 ± 5.8 28.2 ± 5.3
Physical activity data N= 5343 N= 4,810 N= 14,216
Average daily step count, mean ±
SD, steps
3793.8 ± 3,504.6 3244 ± 3,220 3491.1 ± 3345.4 –
Past medical history N= 25,408 N= 27,958 N= 53,366 † N= 50
No reported medical conditions 25,408 (100) – 25,408 (48.3) 25 (50.0)
Essential hypertension – 13,939 (49.9) 13,939 (26.5) 22 (44.0)
Hypercholesterolemia – 15,088 (54.0) 15,088 (28.7) 18 (36.0)
Diabetes – 3505 (12.5) 3505 (6.7) 4 (8.0)
CAD – 3699 (13.2) 3699 (7.0) 0 (0)
Prior MI – 1791 (6.4) 1791 (3.4) 0 (0)
Arrhythmia – 7560 (27.0) 7560 (14.3) 11 (22.0)
CHF – 1172 (4.2) 1172 (2.3) 4 (8.0)
PVD – 1027 (3.7) 1027 (2.0) 0 (0)
Prior stroke – 1458 (5.2) 1458 (2.9) 0 (0)
Sleep Apnea – 6923 (24.8) 6923 (13.2) 0 (0)
Asthma – 5622 (20.1) 5622 (10.7) 0 (0)
COPD – 1685 (6.0) 1685 (3.2) 0 (0)
Medications – N= 35,074 N= 35,074 –
Beta blockers – 2412 (6.8) 2412 (6.8) –
Non-dihydropyridine CCB – 260 (0.7) 260 (0.7) –
Amiodarone – 55 (0.2) 55 (0.2) –
Inhaled beta agonists – 120 (0.3) 120 (0.3) –
BMI body mass index, CAD coronary artery disease, kg kilogram, m meter, cm centimeters, CHF congestive heart failure, COPD chronic obstructive pulmonary
disease, HR heart rate, MI myocardial infarction, PPG photoplethysmography, PVD peripheral vascular disease, SD standard deviation
aThe distribution of all variables between the “no reported medical conditions” data set, the “Individuals with at least one medical condition” data set and the
“full HR” data set are significantly different (p < 0.0005), except the “height” (p= 0.65) and the average daily step counts (p= 0.57) and race/ethnic group
(p= 0.01)
R. Avram et al.
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HR-PPG measurements from 66,788 individuals who provided over
three million data points over a 3-year period. Furthermore, we
describe how demographic and medical factors affect these
norms, including age, gender, race/ethnicity, anthropometric
characteristics, physical activity, and disease state. These data
provide reference ranges of real-world HR for patients and
physicians and establish the foundation for future research, in
which real-world HR might become an outcome for large-scale
studies to understand the evolution of disease at an
international scale.
Higher baseline HR has been shown to be an important
prognostic factor, with higher HR associated with increased all-
cause and cardiovascular mortality.1–5,10 However, previous
studies have shown that HRs measured in clinical settings may
not be representative of real-world HR and may be biased by the
particular clinical conditions for which the ECGs were ordered.1,3
For example, a “white-coat” effect can increase HR,11 leading to
false elevation. Furthermore, ambulatory, real-world HR, has been
found to correlate significantly more with mortality than resting
heart rate obtained in the clinical setting,12 suggesting the need
to update HR norms to reflect real-world, remotely obtained
values.6 The median HR-PPG of 77.6 in healthy individuals of our
cohort was higher than the median HR of 68.0 bpm described by
Mason et al.,3 who studied 79,743 ambulatory subjects that had a
single ECG done in a clinical setting. As we averaged across
multiple measurements per user (median of 60.0 measurements
per user per year), our data may provide a better approximation of
the average real-world HR-PPG compared with a single measure-
ment. The NHANES study followed 20,749 Adults living in the
Table 2. Heart rate according to age, gender, race, and step count in
healthy participants
Baseline
characteristics
Number of
participants
contributing at least
one HR-PPG
measurement N, (%)
Number of HR-PPG
measurements
Median (IQR)
Geometric
mean HR ± SDa
Age stratum N= 25,280
18–20 2197 (8.7) 11.0 (20.0) 81.6 ± 14.0
21–30 6558 (25.9) 15.0 (30.0) 80.2 ± 14.8
31–40 6480 (25.6) 18.0 (37.0) 78.5 ± 15.1
41–50 5620 (22.2) 21.0 (45.0) 75.3 ± 14.3
51–60 3058 (12.1) 23.0 (54.0) 73.9 ± 13.5
61–70 1173 (4.6) 26.0 (54.0) 73.0 ± 12.7
71–80 194 (0.8) 29.5 (72.3) 74.2 ± 11.1
>80 13 (0.1) 36.0 (80.0) 78.1 ± 16.5
Gender N= 18,858
Females 9476 (50.2) 18.0 (38) 79.3 ± 14.0
Males 9382 (49.8) 21.0 (45) 73.8 ± 14.5
Race or
ethnic group
N= 18,727
Non-Hispanic White 14,280 (76.3) 20.0 (43.0) 75.9 ± 14.5
Black or African
American
314 (1.7) 12.0 (36.8) 81.4 ± 14.0
Hispanic, Latino, or
Spanish origin or
ancestry
2001 (10.7) 18.0 (37.0) 78.6 ± 14.3
Asian 1160 (6.2) 17.0 (38.8) 79.2 ± 14.3
Multi-ethnic 526 (2.8) 20.0 (34.0) 78.1 ± 14.4
Other/prefer not to
disclose
440 (2.4) 15 (34.0) 78.2+ 13.0
BMI N= 2175
<18.5 58 21.0 (54.2) 77.9 ± 14.7
≥18.5–25 1027 29.0 (62.0) 74.9 ± 16.5
25–30 686 29.0 (69.0) 73.0 ± 15.1
≥30 404 24.5 (58.8) 80.1 ± 13.3
Daily step count
stratum
N= 5343
100–2000 3646 (68.2) 36.0 (66.0) 78.9 ± 14.4
2001–4000 826 (15.4) 35.0 (72.0) 80.0 ± 13.5
4001–6000 422 (7.9) 39.5 (82.0) 79.0 ± 14.8
6001–8000 241 (4.5) 31.0 (77.0) 77.6 ± 16.4
8001–10,000 113 (2.1) 45.0 (80.0) 77.9 ± 17.3
10,001–12,000 64 (1.2) 23.0 (69.3) 78.0 ± 13.9
12,001–14,000 31 (0.6) 31.0 (37.0) 81.9 ± 15.0
HR-PPG heart rate as measured using photoplethysmography, BMI body
mass index, HR heart rate, SD standard deviation
aAll intergroup comparisons were significant (p < 0.0005)
Fig. 1 Percentile graph of average real-world HR-PPG. a Percentile
graph of average real-world HR-PPG according to the age.
b Percentile graph of average real-world HR-PPG according to the
gender c Percentile graph of average real-world HR-PPG according
to the step counts
R. Avram et al.
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Table 3. Heart rate according to past medical history and medication
Baseline
characteristics
Number of participants
contributing at least one
measurement n (%)
Number of
measurements per
participant median (IQR)
Unadjusted
geometric mean HR-
PPG ± SD (bpm)
P value for
unadjusted HR-
PPG
Age-adjusted
geometric mean
HR-PPG ± SD (bpm)
P value for age-
adjusted means
Self-reported past
medical history
N= 53,366
No medical condition 25,408 (47.6) 18.0 (38.0) 77.6 ± 14.6 <0.0005 75.5 ± 0.2 <0.0005
Presence of at least
one medical condition
27,958 (52.4) 20.0 (47.0) 79.6 ± 14.2 79.5 ± 0.1
Essential hypertension
With 13,939 (26.5) 20.0 (49.0) 79.5 ± 14.1 0.0005 79.9 ± 0.2 <0.0005
Without 38,495 (73.5) 18.0 (42.0) 78.2 ± 14.6 76.7 ± 0.1
Hypercholesterolemia
With 15,088 (28.7) 20.0 (49.0) 78.8 ± 14.0 0.02 79.2 ± 0.2 <0.0005
Without 37, 346 (71.3) 18.0 (42.0) 78.4 ± 14.7 76.7 ± 0.1
Diabetes
With 3505 (6.7) 18.0 (46.0) 82.6 ± 14.1 <0.0005 83.7 ± 0.3 <0.0005
Without 49,635 (93.3) 19.0 (42.0) 78.3 ± 14.5 77.1 ± 0.1
CAD
With 3699 (7.0) 22.0 (55.5) 78.6 ± 14.4 0.77 78.9 ± 0.3 <0.0005
Without 49,331 (93.0) 18.0 (42.0) 78.5 ± 14.5 77.4 ± 0.1
Prior MI
With 1791 (3.4) 20.0 (52.0) 77.9 ± 14.4 0.03 78.5 ± 0.5 0.03
Without 51,575 (9.6) 18.0 (42.0) 78.6 ± 14.5 77.5 ± 0.1
Arrhythmia
With 7560 (14.3) 25.0 (59.0) 81.0 ± 15.3 <0.0005 79.9 ± 0.2 <0.0005
Without 44,867 (85.7) 18.0 (39.0) 78.0 ± 14.3 77.1 ± 0.1
CHF
With 1172 (2.3) 22.0 (59.0) 80.9 ± 13.9 <0.0005 80.6 ± 0.6 <0.0005
Without 52,194 (97.7) 19.0 (42.0) 78.5 ± 14.5 77.5 ± 0.1
PVD
With 1027 (2.0) 20.0 (52.5) 80.0 ± 14.1 <0.0005 80.0 ± 0.7 <0.0005
Without 52,339 (98.0) 19.0 (42.0) 78.5 ± 14.5 77.5 ± 0.1
Prior stroke
With 1458 (2.9) 21.0 (51.0) 80.4 ± 14,0 <0.0005 80.6 ± 0.5 <0.0005
Without 51,908 (96.1) 19.0 (42.0) 78.5 ± 14.4 77.4 ± 0.1
Sleep apnea
With 6923 (13.2) 19.0 (46.0) 81.0 ± 14.2 <0.0005 81.3 ± 0.2 <0.0005
Without 46,443 (86.8) 19.0 (42.0) 77.9 ± 14.5 76.9 ± 0.1
Asthma
With 5622 (10.7) 17.0 (40.0) 81.6+ 14.5 <0.0005 80.1 ± 0.2 <0.0005
Without 47,744 (89.3) 19.0 (43.0) 78.2 ± 14.4 77.2 ± 0.1
COPD
With 1685 (3.2) 18.0 (43.0) 82.5 ± 13.9 <0.0005 82.2 ± 0.5 <0.0005
Without 51,681 (96.8) 19.0 (43.0) 78.3 ± 14.5 77.4 ± 0.1
Medications N= 35,074
Beta blockers
Taking 2412 (6.9) 35.5 (86.0) 77.7 ± 13.3 0.96 78.6 ± 0.3 <0.0005
Non-taking 32,662 (93.1) 22.0 (47.0) 77.7 ± 14.5 77.0 ± 0.1
Non-dihydropyridine CCB
Taking 260 (0.7) 22.0 (49.0) 81.8 ± 14.6 <0.0005 83.3 ± 0.9 <0.0005
Non-taking 34,814 (99.3) 47.0 (97.5) 77.6 ± 14.5 77.1 ± 0.1
Amiodarone
Taking 55 (0.2) 48.0 (137.0) 74.4 ± 12.5 0.09 76.8 ± 1.9 0.84
Non-taking 35,019 (98.2) 22.0 (49.0) 77.7 ± 14.5 77.2 ± 0.1
Inhaled beta agonists
Taking 120 (0.3) 23.0 (60.8) 79.7 ± 18.4 0.04 81.3 ± 1.4 0.003
Non-taking 34,954 (97.7) 22.0 (49.0) 76.5 ± 18.5 77.2 ± 0.1
CAD coronary artery disease, CHF congestive heart failure, COPD chronic obstructive pulmonary disease, CCB calcium channel blockers, HR heart rate, MI
myocardial infarction, PVD peripheral vascular disease, SD standard deviation
aThese values are only reported in “healthy” participants
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United States and described their in-clinic resting HR over 3 years.2
Compared with this study, the corresponding levels of the 5th
percentile were lower in our cohort (50–55 bpm vs 60 bpm), which
demonstrates a discrepancy between HR obtained in-clinic versus
in a real-world setting, whereas in clinic HR tend to be trending
higher than real-world HR.2 Whereas our 95th percentile was
similar among those < 40 years old (104 bpm in both cohorts),
among those > 40 years old, we found a lower 95th percentile
(100 bpm vs 104 bpm),2 which may be due to our repeat
measurements taken outside of the clinic setting, decreasing
variability, and minimizing any “white-coat” heart rate effect.11
Furthermore, we described the circadian evolution of real-world
HR, which allows us to interpret these values according to the time
of day.13 We observed that HR-PPG and HRV levels decline with
age. Our observations suggest that the 95th percentile of real-
world HR-PPG is ≤110 in individuals aged 18–45 years old, ≤100 in
those aged 45–60 and ≤95 bpm in individuals >60 years old. This
decrease in maximum HR-PPG and HRV as people get older is
mainly owing to a sympathetic modulation decline with
aging.10,14,15
A considerable number of epidemiologic studies have demon-
strated a link between a higher HR and increasing burden of
atherosclerosis16 and cardiovascular outcomes1,3–5,17,18 as well as
the existence of a biological gradient between the severity of
atherosclerosis and resting HR.19 Increased HR has been linked to
atherosclerosis risk factors and endothelial dysfunction, plaque
erosion and plaque rupture.20 Furthermore, it is acknowledged
that the stress on the cardiovascular system is better investigated
by real-world measurements rather than measurements obtained
at rest, in a stressful clinic environment.6,12 Real-world HR is more
reproducible than resting HR obtained in clinical setting.21
Therefore, it is possible that real-world measurements would
better correlate than resting HR measurements with cardiovas-
cular outcomes.12 Our study observed a higher HR-PPG for
participants with hypercholesterolemia, hypertension, diabetes,
MI, a prior stroke and peripheral vascular disease, all risk factors or
manifestations of systemic atherosclerosis.1 Similarly, a chronic
increase in sympathetic tone leading to higher HR, as was
observed in our cohort, has been described in patients with COPD,
sleep apnea and asthmatic patients.22–25
In our cohort, women had a higher HR than those of men by 6
bpm, which extends prior observations to the real-world
setting.2,14,26–29 It has been speculated to be owing to women
having, on average, smaller stroke volumes.1,26,28,30 Differences in
resting HR-PPG by race has also been previously reported in
smaller studies of fewer than 170 participants.22,23 Bathula et al.31
Table 4. Multivariable regression models for mean heart rate
Model 1. Multivariable linear regression describing the relationship
between age, gender, daily step count, body mass index and number of
diseases with geometric mean HR-PPG, in 1400 participantsa
Model 2. Multivariable linear regression describing the relationship
between age, gender, disease state and medications with geometric mean
HR-PPG, in 31,393 participantsb
Variable Coefficient 95% CI p value Variable Coefficient 95% CI p value
Age, per 10-year increments −2.59 −3.18–2.01 <0.0005 Age, per 10-year increments −1.93 −2.05–1.81 <0.0005
Gender, for females 4.00 2.40–5.57 <0.0005 Gender, for females 4.28 3.97–4.59 <0.0005
Race or ethnic group <0.0005 Race or ethnic group <0.0005
Non-Hispanic White Ref. – – Non-Hispanic White Ref. –
Black or African American 0.57 −4.21–5.55 0.79 Black or African American 3.00 1.94–4.06 <0.0005
Hispanic, Latino, or Spanish origin or
ancestry
0.37 −2.42–3.17 0.79 Hispanic, Latino, or Spanish origin
or ancestry
1.87 1.38–2.36 <0.0005
Asian 5.65 2.30–8.99 0.001 Asian 3.32 2.67–3.96 <0.0005
Multi-ethnic −0.47 −4.98–4.03 0.84 Multi-ethnic 1.25 0.32–2.18 <0.0005
Other/prefer not to disclose −0.02 −7.27–7.23 1.00 Other/prefer not to disclose 1.82 0.81–2.83 <0.0005
Number of medical conditions, per
medical condition
0.83 0.22–1.44 0.01 Diabetes 4.48 3.78–5.19 <0.0005
Average daily steps, per 1000 steps 0.03 −0.19–0.25 0.79 Arrhythmia 1.65 1.19–2.11 <0.0005
BMI 0.21 0.08–0.34 0.001 Sleep apnea 3.67 3.19–4.16 <0.0005
CCB, non-dihydropyridine 4.11 2.33–5.89 <0.0005
COPD 2.49 1.50–3.48 <0.0005
Asthma 1.51 0.99–2.03 <0.0005
Hypertension 1.83 1.43–2.23 <0.0005
Hypercholesterolemia 1.35 0.98–1.72 <0.0005
Beta agonists 2.58 −0.10–5.26 0.06
Beta blockers −0.48 −1.12–0.16 0.14
Amiodarone −2.07 −5.95–1.81 0.30
CAD −0.28 −1.12–0.56 0.51
Prior MI −0.25 −1.43–0.94 0.68
PVD 0.28 −1.20 −1.75 0.72
Prior stroke 0.64 −0.43–1.71 0.24
CHF 0.36 −1.05–1.77 0.62
BMI body mass Index, CAD coronary artery disease, CCB calcium channel blockers, non-dihydropyridine, CHF congestive heart failure, CI confidence interval,
COPD chronic obstructive pulmonary disease, HR heart rate, PPG photoplethysmography, PVD peripheral vascular disease, MI myocardial Infarction, y years
aWe had 1400 observations for model 1, owing to the inclusion of step counts and BMI as a predictor. The adjusted R2 was 0.01; P < 0.0005.
bWe had 31,393 observations for model 2. The adjusted R2 was 0.09; P < 0.0005
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demonstrated that on average, South Asians have 5 bpm higher
HR-PPG than Europeans, findings that seemed genetically driven
and were not related to other risk factors. Our cohort extends prior
literature, by demonstrating within a larger sample size that
African Americans had the highest HR-PPG. These racial differ-
ences may be explained by distinct genetic phenotypes, leading
to a different neural control of HR-PPG in African Americans
compared with Non-Hispanic Whites.14 We also observed an
increase in HR-PPG and a reduction of HRV with increasing BMI,
where individuals with a BMI ≥ 30 had a higher HR-PPG compared
with their “normal weight” counterparts. These data reveal that
obesity is associated with higher HRs, suggesting that weight loss
may lead to lower HR and better overall health.18,32 Large-scale
epidemiological studies involving 13,761 adults, demonstrated the
link between an activation of the sympathetic nervous system,
increased HR, and pulse pressure and BMI.32 Furthermore, we
observed a “U-shaped” relationship with BMI and HR, where both
underweight and overweight participants demonstrate an
increase in HR compared with their ‘normal weights’ counterparts,
complementing prior findings from the literature.33 We detected a
reduction in HR with height, whereas the taller the person, the
lower the heart rate was, extending prior findings from the
literature.34 Our large sample enabled us to describe the real-
world HR-PPG distribution according to daily step count strata. We
observed that individuals with a higher activity level as measured
by step counts had a lower HR-PPG and a higher HRV, which is
consistent with prior studies.35–37 We also showed that for an
increase of 5000 steps, the average resting HR-PPG decreased by
1 bpm, up to ~8000 steps/day. However, step count was not a
significant predictor of reduced HR-PPG after multivariable
adjustment, suggesting that the benefits of increased step counts
might be difficult to disentangle from the effects of age, gender or
racial differences. Our findings extend prior findings by being the
largest cohort of real-world HR measures to date, reinforcing the
notion that individual characteristics such as age, gender,
ethnicity, step counts, and BMI should be taken into account
when interpreting HR values in the clinical setting. Using repeated,
real-world, HR-PPG data obtained from wearables or apps data
could enable physicians to provide personalized HR goals to a
level that was before unattainable.9
In this study, we have shown that HR-PPG measurements are
valid, and our nomograms of HR-PPG measurements obtained by
patients remotely can now be interpreted by physicians, across a
wide variety of patient phenotypes. These data can inform
Table 5. Multivariable regression models for intra-user standard deviation of heart rate measurements
Model 1. Multivariable linear regression describing the relationship
between age, gender, daily step count, body mass index and number
of diseases with geometric mean HR-PPG in 1652 participantsa
Model 2. Multivariable linear regression describing the relationship between
age, gender, disease state, and medications with intra-user standard
deviation of HR-PPG, in 30,700 participantsb
Variable Coefficient 95% CI p-value Variable Coefficient 95% CI p-value
Age, per 10-year increments −0.47 −0.79–0.14 0.01 Age, per 10-year increments −0.45 −0.53–0.37 <0.0005
Gender, for females 0.34 −0.54–1.28 0.45 Gender, for females −0.48 −0.69–0.27 <0.0005
Race or ethnic group Race or ethnic group <0.0005
Non-Hispanic White Ref. – Non-Hispanic White Ref. –
Black or African American −0.06 −2.77–2.64 0.96 Black or African American 0.61 −0.09–1.31 0.09
Hispanic, Latino, or Spanish origin
or ancestry
0.28 −1.27–1.83 0.72 Hispanic, Latino, or Spanish origin or
ancestry
0.65 0.33–0.98 <0.0005
Asian 0.17 −1.69–2.03 0.86 Asian 0.09 −0.34–0.52 0.67
Multi-ethnic −0.85 −3.35–1.64 0.50 Multi-ethnic 0.19 −0.42–0.81 0.81
Other/prefer not to disclose −0.60 −4.62–3.42 0.77 Other/prefer not to disclose −0.31 −0.98–0.36 0.36
Number of medical conditions, per medical condition
0.07 −0.28–0.41 0.70 Diabetes −0.28 −0.75–0.19 0.24
Average daily steps, per 1000 steps 0.15 0.03–0.28 0.02 Arrhythmia 0.89 0.59–1.19 <0.0005
BMI −0.10 −0.18–0.03 0.01 Sleep apnea 0.63 0.30–0.95 <0.0005
Non-dihydropyridine CCB 3.92 2.18–5.67 <0.0005
COPD −0.22 −0.88–0.43 0.50
Asthma −0.29 −0.63–0.05 0.10
Hypertension −0.47 −0.73–0.20 <0.0005
Hypercholesterolemia −0.08 −0.32–0.17 0.55
Beta agonists 0.10 −1.65–1.86 0.91
Beta blockers 0.002 −0.419–0.423 0.99
Amiodarone 1.01 −1.61– 3.62 0.45
CAD −0.13 0.70–0.42 0.65
Prior MI 0.26 −0.53–1.04 0.52
PVD 0.45 −0.51–1.42 0.36
Prior stroke 0.49 −0.22–1.20 0.17
CHF −0.24 −1.17–0.69 0.61
BMI body mass Index, CAD coronary artery disease, CCB calcium channel blockers, non-dihydropyridine, CHF congestive heart failure, CI confidence interval,
COPD chronic obstructive pulmonary disease, HR heart rate, PPG photoplethysmography, PVD peripheral vascular disease, MI myocardial Infarction, y year
aWe had 142 observations for model 1, owing to the inclusion of step counts and BMI as a predictor. The adjusted R2 was 0.01; P= 0.001
bWe had 30,700 observations for model 2. The adjusted R2 was 0.009; P < 0.0005
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patients about physical fitness and could help providers offer
counseling on lifestyle changes or provide overall encouragement
and support based on these real-world HR norms.9
Our study has several important limitations. Our enrollment of
individuals who downloaded the Instant Heart Rate app may be
associated with higher socioeconomic status, technological
awareness, and knowledge of elevated cardiovascular risk factors.
Our validation cohort comprised of consecutive patients referred
to the cardiovascular clinic differing from the general population,
which could limit generalizability. However, our validation was
purposefully designed to look at a broader spectrum of people
who might use the app-based PPG for HR measurements,
including more people with abnormal ECGs and cardiovascular
disease in whom PPG might be expected to be less accurate.
Despite this, we demonstrated a high validity of these measure-
ments, in line with previously published literature.
The PPG in our data was obtained using a specific app and
accuracy of measurement may vary based on different user
interfaces to ensure adequate contact and signal processing
algorithms that may occur in different PPG approaches. In
addition, as users recorded HR-PPG measurements on demand,
rather than being passively monitored, available HR-PPG do not
reflect all possible real-world HR and our nomograms might not
generalize to HR values measured passively by wearables. In
addition, we did not have the context around the measurements
(i.e., food intake, post exercise, palpitations, etc.), which may have
influenced the HR values. For example, in the “known resting HR
data set”, we observed an average HR 2.8 bpm higher than in our
full HR data set. One plausible explanation for this finding is that
patients might be measuring their HR at rest, while having
palpitations, leading to a higher upper boundary of HR in this data
set and dragging the average HR higher. However, our high
number of measurements collected per user in the full HR data
set, combined with our large cohort size was able to describe the
variability of HR according to age, gender, race, or BMI. Although
the relationship between HR-PPG and step count confirms prior
literature, our absolute values of step count may be under-
estimated owing to non-carrying time of the smartphone.36
Therefore, our findings should be interpreted with caution,
especially in those >8000 average daily step counts, which
represent a very small subset of participants in our study. The
Health eHeart Study population is less racially, ethnically and
geographically diverse and of a higher socioeconomic status than
the average United States population, so care must be taken in
applying these results to other populations with different
characteristics.18,33 However, our population is likely representa-
tive of participants who are most likely to use this kind of
technology. Owing to the cross-sectional nature of our study
design, we were unable to investigate incident disease states and
its relationship with HR-PPG and this should be examined in future
studies. In addition, although self-reports of medical diagnoses in
the HeH study is reliable,37 it may suffer from recall bias and social
desirability biases.
Using a unique, real-world cohort that is the largest of its kind,
we were able to describe the distribution of real-world HR-PPG
among patients by means of remotely measured, smartphone-
based PPG measurements. Our findings add granularity to the
distribution of HR in specific subgroups not previously described
and may assist physicians to interpret remotely obtained, real-
world, on-demand, HR-PPG values measured by patients across a
wide variety of patient phenotypes and medical conditions.
METHODS
Study design
We first performed an in-person validation study of the app to determine
its accuracy in assessing HR-PPG. We then analyzed 3,144,332 HR-PPG
signals from 66,788 participants obtained using the app as part of the
Health eHeart Study in a cross-sectional population-based study.
Smartphone-based PPG validation study
In order to validate the accuracy of the app-based HR-PPG signal, we
simultaneously recorded a 10-second HR-ECG and HR-PPG in 50
consecutive participants referred to Cardiology clinic at UCSF, after 5 min
of rest. Mean differences were computed between successive cardiac
cycles of HR-PPG and HR-ECG, in milliseconds and bpm. Rhythms were
classified as being normal (sinus rhythm) or abnormal and by their
regularity. Irregular rhythms included atrial fibrillation, premature ventri-
cular, or atrial contractions and atrial flutter with variable
atrioventricular block.
HR-PPG measurements were obtained using the Instant Heart Rate app
(Azumio inc), a popular application for measuring HR and a smartphone’s
(any Apple© model or Android© phone model) camera and light.38 PPG
recordings are obtained “on demand” by the user steadily applying the
pulp of their finger on the smartphone camera and thus is an on-demand
measurement, as opposed to passive measurements made by some
wearables. Participants were free to measure HR at any frequency and time
of day. The study team did not provide additional instructions on when to
measure such HR measurements.
Population study design
We performed a cross-sectional analysis of data obtained from 1 April 2014
and 30 April 2018 from consecutive participants enrolled in the Health
eHeart (HeH) Study—a worldwide, internet-based, longitudinal eCohort.
English-speaking adults, 18 years or order, with an email address were
eligible to join.39 The Health eHeart Study participants complete online
surveys relating to demographics, physical activity levels, medical
conditions, and medications in order to allow for the collection of patient
reported outcomes and allows for connecting devices and apps (such as
those that count steps) to the study.39 The study was approved by the
UCSF Institutional Review Board and informed consent was obtained from
all participants. For the analysis of HR-PPG, we included all Health eHeart
Study participants that recorded at least one HR-PPG measurement and
connected their Azumio account to the Health eHeart Study.
Participants were actively recruited through a variety of campaigns at
UCSF (through clinics and electronically delivered invitations) and by
partner organizations (e.g., American Heart Association), and passively
recruited through word of mouth and press releases. For the first data
collection set (“eVisit”), participants were asked to answer questions
regarding the basic demographics, previous medical history and medica-
tions. We calculated body mass index from self-reported weight and
height and classified individuals as normal weight (BMI ≥ 18.5 – < 25),
overweight (BMI 25–30) and obese (BMI ≥ 30). We derived the following
medication classes based on medication survey answers: beta blockers,
beta agonists, amiodarone and non-dihydropyridine calcium channel
blocks (CCB).
Data collection
Heart rate measures using PPG were obtained using the Instant Heart Rate
(Azumio, Inc) smartphone app on either Android or iOS operating systems
and the smartphone camera. Resultant changes in reflected light intensity
are interpreted by an algorithm as pulsatile blood volume changes, which
is then translated into HR. At least 15 seconds of PPG signal, sampled at
100–120 Hz, were collected. Signals were processed to identify the rising
edge in order to identify beat to beat intervals and calculate an average HR
over the recording interval (Supplementary Fig. 1). If the underlying
rhythm was an arrhythmia (atrial fibrillation, atrial flutter, premature
ventricular contractions, supraventricular tachycardia), we used the peak of
each HR-PPG waveform instead of the rising edge. Although it is difficult to
record accurate HR measures during physical exertion, HR measurements
taken immediately after a physical activity are possible.
Weighting of repeated HR measurements
To account for repeated measures, HR and 24-hour step counts were log-
transformed to approximate normality and the geometrical mean for each
participant was calculated.40 To obtain the weights, we used linear mixed
models with random intercepts to estimate the ICC of the repeated log-
transformed measures. Then the weight for each participant was
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calculated as weighti ¼ Ni1þICCðNi1Þ
 
, where Ni is the number of repeated
HR measures for participants I. The denominator of the weight represents
the inflation of the variance of the participant-specific means owing to the
correlation of the repeated measures. In a final step, the weights were
normalized to sum to the number of participants. If the repeated measures
were independent (ICC= 0), then participants would be weighted in
proportion to their number of observations; at the other extreme, if the
repeated measures were perfectly correlated (ICC= 1), then the geometric
mean for each participant would be given equal weight. We then used
weighted linear models to examine the independent correlates of
geometric mean HR.
Statistical analysis
Continuous variables are presented using mean ± standard deviation (SD)
or median (interquartile range) and were compared using the t test, the
Mann–Whitney test or one-way analysis of variance, as appropriate.
Categorical variables are presented as frequencies (percentages) and
compared using either Chi-square or Fisher’s exact tests. For our validation
study, we estimated ICC for agreement between HR-ECG values obtained
in clinic, using a 12-lead ECG, with the HR-PPG obtained using the Azumio
app, at the heart rate level and at the signal level, by comparing averaged
R–R intervals between both methods. We also used a Bland–Altman plot to
assess agreement between the simultaneous HR-PPG and HR-ECG
recordings.41
To clean the data, we excluded outliers defined as values of HR-PPG
outside of the biologically plausible range of 20–220 bpm.16 Next, to better
limit the data to values most likely to be true resting values (not affected
by physical activity), we created a “known resting HR data set”. To do this,
we restricted our HR-PPG measurements to participants who had
accumulated between 10 and 25 steps during the 30min prior to their
HR-PPG measurements, assuming that >25 steps represented the lower
limit of any exercise in the last 30 min, whereas <10 steps might reflect
users who set the phone down while exercising. We excluded participants
with a medical condition from this data set. For our analyses, we
summarized the repeated HR-PPG measurements for each participant,
within our “known resting HR data set” and the “full HR data set” using
weighted geometric means. As a measure of dispersion of the geometric
mean HR-PPG, we used 95% prediction intervals, accounting for both the
standard error of the overall mean and the residual variation of the
participant-specific geometric means. We used a non-parametric kernel
regression method to create centile charts for heart rate and step counts
with respect to age, gender, and step count.
In the subgroup with at least one medical condition, we used
unadjusted and age-adjusted HR-PPG to examine the independent
associations of comorbidities with geometric mean HR-PPG. Univariable
linear regression models were fitted to describe the relationship between
age, gender, race/ethnicity, body mass index (BMI), height, weight, step
count, and number of medical conditions. Furthermore, two multivariable
linear regression models were fitted to examine the associations between
HR and demographics or comorbidities, after assessing for heteroscedas-
ticity and multicollinearity between the variables. The first included age,
gender, race/ethnicity, number of medical conditions, BMI and step count,
and the second included age, gender, individual medical conditions,
medication use (beta blockers, amiodarone, beta agonists, and CCB). In an
exploratory analysis presented in the appendix, selected interactions
between medical conditions and medications were also included.
Furthermore, we calculated person-based HRV, in beats per minute, by
deriving the standard deviation of R–R intervals of HR-PPG within users
with more than two recordings. We then fitted two multivariable
regression models to examine the relationship between HRV and age,
gender, medical conditions, BMI, and step count. We also derived average
values of real-world HR-PPG and HRV based on time of day, based on
weekend vs weekdays and based on seasons.
Two-tailed p values < 0.01 were considered statistically significant,
without further correction for multiple testing. Statistical analyses were
performed using STATA 15.1 (College Station, TX) and python 2.7 with
packages scientific python version 0.19.1, scikit learn version 0.19.0.
Reporting summary
Further information on research design is available in the Nature Research
Reporting Summary linked to this article.
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